GT Biopharma (GTBP) Competitors $0.73 -0.07 (-9.25%) As of 10:45 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GTBP vs. SNGX, TXMD, LGVN, HCWB, BFRG, IMCC, MRKR, LPTX, MBRX, and GOVXShould you be buying GT Biopharma stock or one of its competitors? The main competitors of GT Biopharma include Soligenix (SNGX), TherapeuticsMD (TXMD), Longeveron (LGVN), HCW Biologics (HCWB), Bullfrog AI (BFRG), IM Cannabis (IMCC), Marker Therapeutics (MRKR), Leap Therapeutics (LPTX), Moleculin Biotech (MBRX), and GeoVax Labs (GOVX). These companies are all part of the "pharmaceutical products" industry. GT Biopharma vs. Its Competitors Soligenix TherapeuticsMD Longeveron HCW Biologics Bullfrog AI IM Cannabis Marker Therapeutics Leap Therapeutics Moleculin Biotech GeoVax Labs Soligenix (NASDAQ:SNGX) and GT Biopharma (NASDAQ:GTBP) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and risk. Do analysts prefer SNGX or GTBP? Soligenix presently has a consensus target price of $6.00, indicating a potential upside of 110.97%. GT Biopharma has a consensus target price of $11.00, indicating a potential upside of 1,415.15%. Given GT Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe GT Biopharma is more favorable than Soligenix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Soligenix 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00GT Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Do institutionals and insiders believe in SNGX or GTBP? 3.6% of Soligenix shares are owned by institutional investors. Comparatively, 8.2% of GT Biopharma shares are owned by institutional investors. 3.1% of Soligenix shares are owned by insiders. Comparatively, 3.4% of GT Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media favor SNGX or GTBP? In the previous week, GT Biopharma had 1 more articles in the media than Soligenix. MarketBeat recorded 4 mentions for GT Biopharma and 3 mentions for Soligenix. GT Biopharma's average media sentiment score of 0.64 beat Soligenix's score of 0.64 indicating that GT Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Soligenix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GT Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, SNGX or GTBP? Soligenix has a beta of 2.05, meaning that its share price is 105% more volatile than the S&P 500. Comparatively, GT Biopharma has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500. Which has better valuation and earnings, SNGX or GTBP? Soligenix has higher revenue and earnings than GT Biopharma. Soligenix is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSoligenix$120K101.67-$8.27M-$3.80-0.75GT BiopharmaN/AN/A-$13.16M-$4.07-0.18 Is SNGX or GTBP more profitable? Soligenix's return on equity of -274.76% beat GT Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets SoligenixN/A -274.76% -129.20% GT Biopharma N/A -1,804.34%-200.12% SummaryGT Biopharma beats Soligenix on 8 of the 14 factors compared between the two stocks. Get GT Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for GTBP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GTBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GTBP vs. The Competition Export to ExcelMetricGT BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.59M$3.18B$5.80B$10.10BDividend YieldN/A2.26%5.25%4.56%P/E Ratio-0.1821.6275.8126.14Price / SalesN/A454.04536.55119.56Price / CashN/A45.8737.4259.95Price / Book-0.979.6511.756.24Net Income-$13.16M-$53.33M$3.29B$270.65M7 Day Performance-21.85%2.75%1.57%3.48%1 Month Performance-58.28%12.61%8.46%7.86%1 Year Performance-65.75%13.95%63.87%27.53% GT Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GTBPGT Biopharma2.4952 of 5 stars$0.73-9.3%$11.00+1,415.2%-61.3%$2.59MN/A-0.188Short Interest ↓SNGXSoligenix2.2969 of 5 stars$3.10+1.3%$6.00+93.5%-21.5%$13.28M$120K-0.8220Short Interest ↓TXMDTherapeuticsMD0.7187 of 5 stars$1.11-0.9%N/A-38.2%$12.85M$1.76M0.00420Positive NewsLGVNLongeveron2.9136 of 5 stars$0.83-0.2%$7.67+825.8%-60.8%$12.57M$2.39M-0.1320HCWBHCW Biologics3.0764 of 5 stars$5.72+0.7%$35.00+511.9%-84.8%$12.31M$2.57M-0.4140Short Interest ↑BFRGBullfrog AI0.8631 of 5 stars$1.21-1.6%N/A-48.8%$12.20M$60K-1.594IMCCIM Cannabis0.7692 of 5 stars$2.32-4.9%N/A-10.9%$12.17M$39.44M-4.30340Positive NewsGap DownMRKRMarker Therapeutics3.7734 of 5 stars$0.93+3.3%$13.17+1,322.3%-66.3%$11.98M$6.59M-0.6860Positive NewsShort Interest ↓Gap DownLPTXLeap Therapeutics1.8632 of 5 stars$0.29-2.3%$3.38+1,070.2%-90.0%$11.95MN/A-0.1840Positive NewsMBRXMoleculin Biotech3.4133 of 5 stars$0.39-0.2%$4.00+919.4%-83.9%$11.88MN/A0.0020Analyst ForecastGOVXGeoVax Labs2.5258 of 5 stars$0.75+0.1%$8.50+1,040.0%-79.0%$11.87M$3.95M-0.3710Positive News Related Companies and Tools Related Companies Soligenix Alternatives TherapeuticsMD Alternatives Longeveron Alternatives HCW Biologics Alternatives Bullfrog AI Alternatives IM Cannabis Alternatives Marker Therapeutics Alternatives Leap Therapeutics Alternatives Moleculin Biotech Alternatives GeoVax Labs Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GTBP) was last updated on 9/11/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBuffett, Gates and Bezos Dumping StocksThe world's wealthiest individuals are making huge moves with their money. Warren Buffett just liquidated b...Banyan Hill Publishing | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GT Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GT Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GTBP Stock Alerts